FDA Disputes AstraZeneca's Seroquel Exclusivity Claims
The U.S. Food and Drug Administration said Wednesday that there was no legal basis to AstraZeneca PLC's bid to overturn approval of generic versions of its antipsychotic Seroquel on grounds that...To view the full article, register now.
Already a subscriber? Click here to view full article